+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Malabsorption Syndrome Market by Treatment (Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents), Disease Type (Cystic Fibrosis, Lactose Intolerance, Sprue), End-user - Forecast 2024-2030- Product Image
Global Malabsorption Syndrome Market by Treatment (Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents), Disease Type (Cystic Fibrosis, Lactose Intolerance, Sprue), End-user - Forecast 2024-2030- Product Image
Sale

Global Malabsorption Syndrome Market by Treatment (Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents), Disease Type (Cystic Fibrosis, Lactose Intolerance, Sprue), End-user - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674664
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Malabsorption Syndrome Market size was estimated at USD 2.34 billion in 2023, USD 2.49 billion in 2024, and is expected to grow at a CAGR of 5.66% to reach USD 3.45 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Malabsorption Syndrome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Malabsorption Syndrome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Malabsorption Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Aché Laboratórios Farmacêuticos S.A., AstraZeneca PLC, Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Koninklijke Philips N.V., Merck & Co., Inc., Novartis AG, Perrigo Company PLC, Pfizer Inc., Sanofi S.A., and Tillotts Pharma AG.

Market Segmentation & Coverage

This research report categorizes the Malabsorption Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Anti-Inflammatory Drugs
    • Antibiotics
    • Antidiarrheal Agents
    • Gluten-Free Diet
    • Nutritional Supplements
    • Protease & Lipase Supplements
  • Disease Type
    • Cystic Fibrosis
    • Lactose Intolerance
    • Sprue
  • End-user
    • Academic & Research Institutes
    • Hospitals
    • Nutrition Clinics
    • Pharmaceutical Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Malabsorption Syndrome Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Malabsorption Syndrome Market?
  3. What are the technology trends and regulatory frameworks in the Malabsorption Syndrome Market?
  4. What is the market share of the leading vendors in the Malabsorption Syndrome Market?
  5. Which modes and strategic moves are suitable for entering the Malabsorption Syndrome Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Malabsorption Syndrome Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of lactose intolerance consumers
5.1.1.2. Favorable government initiatives and awareness campaigns for malabsorption syndrome
5.1.1.3. Growing incidences of cause disorders such as celiac disease and other digestive diseases
5.1.2. Restraints
5.1.2.1. Lack of proper healthcare infrastructure
5.1.3. Opportunities
5.1.3.1. Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
5.1.3.2. Investments and development of novel medicines
5.1.4. Challenges
5.1.4.1. Stringent safety rules and product recalls
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Malabsorption Syndrome Market, by Treatment
6.1. Introduction
6.2. Anti-Inflammatory Drugs
6.3. Antibiotics
6.4. Antidiarrheal Agents
6.5. Gluten-Free Diet
6.6. Nutritional Supplements
6.7. Protease & Lipase Supplements
7. Malabsorption Syndrome Market, by Disease Type
7.1. Introduction
7.2. Cystic Fibrosis
7.3. Lactose Intolerance
7.4. Sprue
8. Malabsorption Syndrome Market, by End-user
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Hospitals
8.4. Nutrition Clinics
8.5. Pharmaceutical Companies
9. Americas Malabsorption Syndrome Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Malabsorption Syndrome Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Malabsorption Syndrome Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbvie Inc.
13.1.2. Aché Laboratórios Farmacêuticos S.A.
13.1.3. AstraZeneca PLC
13.1.4. Bausch Health Companies Inc.
13.1.5. Baxter International Inc.
13.1.6. Bayer AG
13.1.7. Gilead Sciences, Inc.
13.1.8. GlaxoSmithKline PLC
13.1.9. Koninklijke Philips N.V.
13.1.10. Merck & Co., Inc.
13.1.11. Novartis AG
13.1.12. Perrigo Company PLC
13.1.13. Pfizer Inc.
13.1.14. Sanofi S.A.
13.1.15. Tillotts Pharma AG
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. MALABSORPTION SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. MALABSORPTION SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MALABSORPTION SYNDROME MARKET DYNAMICS
FIGURE 7. MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 8. MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 10. MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. MALABSORPTION SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 6. MALABSORPTION SYNDROME MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MALABSORPTION SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. MALABSORPTION SYNDROME MARKET SIZE, BY ANTIDIARRHEAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MALABSORPTION SYNDROME MARKET SIZE, BY GLUTEN-FREE DIET, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. MALABSORPTION SYNDROME MARKET SIZE, BY PROTEASE & LIPASE SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 13. MALABSORPTION SYNDROME MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. MALABSORPTION SYNDROME MARKET SIZE, BY LACTOSE INTOLERANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. MALABSORPTION SYNDROME MARKET SIZE, BY SPRUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 17. MALABSORPTION SYNDROME MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. MALABSORPTION SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITION CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 32. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 33. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 50. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 59. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 77. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 87. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 93. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 105. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 114. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 117. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 119. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 120. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 141. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 149. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
TABLE 150. MALABSORPTION SYNDROME MARKET LICENSE & PRICING

Companies Mentioned

  • Abbvie Inc.
  • Aché Laboratórios Farmacêuticos S.A.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Koninklijke Philips N.V.
  • Merck & Co., Inc.
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Sanofi S.A.
  • Tillotts Pharma AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.49 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.45 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Malabsorption Syndrome Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Malabsorption Syndrome Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From
Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 190 Pages
  • Global
From
Blind Loop Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Blind Loop Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 182 Pages
  • Global
From
Short Bowel Syndrome - Epidemiology Forecast - 2034 - Product Image

Short Bowel Syndrome - Epidemiology Forecast - 2034

  • Report
  • 66 Pages
  • Global
From
Short Bowel Syndrome Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

Short Bowel Syndrome Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • 132 Pages
  • Global
From

About the Malabsorption Syndrome Drug Market

Malabsorption Syndrome Drugs are a type of Gastrointestinal Drugs used to treat malabsorption syndrome, a condition in which the body is unable to absorb nutrients from food. These drugs are used to replace the missing nutrients and help the body absorb them. Commonly used drugs include pancreatic enzymes, bile acid sequestrants, and probiotics. Pancreatic enzymes are used to replace the enzymes that the pancreas is unable to produce, while bile acid sequestrants are used to bind bile acids and prevent them from being reabsorbed. Probiotics are used to restore the balance of beneficial bacteria in the gut. Some companies in the Malabsorption Syndrome Drug market include AbbVie, Allergan, AstraZeneca, Bayer, GlaxoSmithKline, Merck, Novartis, Pfizer, and Takeda. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.